Pharnext Makes New Appointments
This article was originally published in Scrip
Executive Summary
Neurologically focused Pharnext has appointed Niall Murphy chief scientific officer and Pierre Schwich chief financial officer (CFO). Schwich brings over 35 years of financial experience to the company and prior to joining Pharnext, he was CFO for Cellectis. Murphy is a professor at the department of psychiatry and biobehavioral sciences and a member of the brain research institute at the David Geffen School of Medicine at UCLA.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.